A number of targeted small-molecule inhibitors targeting active kinases (e.g., EGFR, PDGFRa, PI3K, etc.)or MMPs [256] have been evaluated as single agents or in combination with standard of care for recurrent and newly diagnosed GBM. Here, EGFR is linked to glioblastoma.